BlackRock, Inc. Increases Stake in 4D Molecular Therapeutics, Inc.

BlackRock, Inc. has filed a Schedule 13G/A amendment, disclosing an increased ownership in 4D Molecular Therapeutics, Inc. The filing reveals that BlackRock now beneficially owns 3,062,596 shares, representing 6.6% of the company's common stock. This marks a significant increase from previous holdings, with the value of the shares rising by 367.56% to $3,556,163,971.36. The shares are held in the ordinary course of business and are not intended to influence the control of the issuer. The filing also includes certifications confirming that the shares were not acquired for the purpose of changing or influencing the control of the issuer.